Savalopide-2
Description_Effects
Savalopide-2 contains Elobixibat 2 mg, a novel gastrointestinal agent used for the treatment of Chronic Idiopathic Constipation (CIC) — a long-term condition characterized by infrequent, difficult, or incomplete bowel movements with no identifiable underlying cause. Elobixibat works locally in the intestines by inhibiting the ileal bile acid transporter (IBAT), which increases bile acid concentration in the colon. This action stimulates intestinal fluid secretion and motility, helping to soften stools and promote regular bowel movements. Unlike traditional laxatives, Savalopide-2 targets the underlying motility dysfunction, providing a more natural and sustained approach to bowel regulation. It is especially beneficial for patients who do not respond well to dietary fiber, osmotic laxatives, or stimulant laxatives. Improvement in symptoms such as bloating, abdominal discomfort, and straining is typically observed within a few days of consistent use. Savalopide-2 is usually taken once daily before breakfast, as prescribed by a physician. Common side effects may include mild abdominal pain, diarrhea, or flatulence, which generally subside with continued use. With its targeted mechanism and favorable safety profile, Savalopide-2 offers a clinically effective and patient-friendly option for managing chronic idiopathic constipation and improving gastrointestinal health and comfort.
